Detalhe da pesquisa
1.
Ruxolitinib in patients with polycythemia vera resistant and/or intolerant to hydroxyurea: European observational study.
Eur J Haematol
; 112(3): 379-391, 2024 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-37899734
2.
COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report.
Br J Haematol
; 196(3): 559-565, 2022 02.
Artigo
Inglês
| MEDLINE | ID: mdl-34636033
3.
Antimicrobial prophylaxis in patients with immune thrombocytopenia treated with rituximab: a retrospective multicenter analysis.
Ann Hematol
; 100(3): 653-659, 2021 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-33495923
4.
Isolated Nodal TBC Reactivation in a Patient with Post-Thrombocythemia Myelofibrosis Treated with Ruxolitinib: Case Report and Review of the Literature.
Chemotherapy
; 66(3): 87-91, 2021.
Artigo
Inglês
| MEDLINE | ID: mdl-33784668
5.
Cardiovascular Toxicity in Cancer Patients Treated with Tyrosine Kinase Inhibitors: A Real-World Single-Center Experience.
Oncology
; 98(7): 445-451, 2020.
Artigo
Inglês
| MEDLINE | ID: mdl-32348984
6.
Coexistence of Von Willebrand disease and gastrointestinal stromal tumor (G.I.S.T): Case report of a rare and challenge association.
Transfus Apher Sci
; 59(4): 102805, 2020 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-32444278
7.
Management of Ponatinib in Patients with Chronic Myeloid Leukemia with Cardiovascular Risk Factors.
Chemotherapy
; 64(4): 205-209, 2019.
Artigo
Inglês
| MEDLINE | ID: mdl-31825920
8.
Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib.
Int J Mol Sci
; 20(9)2019 May 06.
Artigo
Inglês
| MEDLINE | ID: mdl-31064152
9.
Low-dose ponatinib is a good option in chronic myeloid leukemia patients intolerant to previous TKIs.
Am J Hematol
; 95(10): E260-E263, 2020 10.
Artigo
Inglês
| MEDLINE | ID: mdl-32557788
10.
Cardiovascular risk factor in MPN patients.
J Thromb Thrombolysis
; 50(3): 640-641, 2020 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-32002767
11.
Age at diagnosis is an important prognostic factor in Philadelphia-negative Myeloproliferative Neoplasms.
Eur J Haematol
; 103(2): 140-141, 2019 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-31121064
12.
Triple-Negativity Identifies a Subgroup of Patients with Better Overall Survival in Essential Thrombocythemia.
Hematol Rep
; 14(3): 265-269, 2022 Aug 24.
Artigo
Inglês
| MEDLINE | ID: mdl-36135321
13.
Familial essential thrombocythemia: 6 cases from a mono-institutional series.
Clin Case Rep
; 10(3): e05525, 2022 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-35251652
14.
Cardiovascular Issues in Tyrosine Kinase Inhibitors Treatments for Chronic Myeloid Leukemia: A Review.
Front Physiol
; 12: 675811, 2021.
Artigo
Inglês
| MEDLINE | ID: mdl-34290617
15.
The Essential Thrombocythemia in 2020: What We Know and Where We Still Have to Dig Deep.
Clin Med Insights Blood Disord
; 13: 2634853520978210, 2020.
Artigo
Inglês
| MEDLINE | ID: mdl-33447121
16.
Cardiovascular Risk in Polycythemia Vera: Thrombotic Risk and Survival: Can Cytoreductive Therapy Be Useful in Patients with Low-Risk Polycythemia Vera with Cardiovascular Risk Factors?
Oncol Res Treat
; 43(10): 526-530, 2020.
Artigo
Inglês
| MEDLINE | ID: mdl-32772025
17.
The Essential Thrombocythemia, Thrombotic Risk Stratification, and Cardiovascular Risk Factors.
Adv Hematol
; 2020: 9124821, 2020.
Artigo
Inglês
| MEDLINE | ID: mdl-32280344
18.
Cardiovascular Risk in Essential Thrombocythemia and Polycythemia Vera: Thrombotic Risk and Survival.
Mediterr J Hematol Infect Dis
; 12(1): e2020008, 2020.
Artigo
Inglês
| MEDLINE | ID: mdl-31934318
19.
Splenomegaly impacts prognosis in essential thrombocythemia and polycythemia vera: A single center study.
Hematol Rep
; 11(4): 8281, 2019 Nov 29.
Artigo
Inglês
| MEDLINE | ID: mdl-31871612
20.
Detection and Clinical Implications of a Novel BCR-ABL1 E12A2 Insertion/Deletion in a CML Patient Expressing the E13A2 Isoform.
Anticancer Res
; 39(12): 6965-6971, 2019 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-31810968